An 11-year-old boy who received Eli Lilly’s experimental gene therapy for hearing loss last October showed signs of restored hearing 30 days after treatment, the pharma giant announced on Tuesday.
The therapy, dubbed AK-OTOF, is designed to deliver a functional copy of a gene called otoferlin. Without otoferlin, auditory signals received by the ear aren’t transmitted to the brain. Lilly estimates that 200,000 people worldwide experience hearing loss caused by mutations to otoferlin.
The company is testing AK-OTOF in a Phase I/II trial enrolling 14 patients, according to the clinical trials registry. The first child dosed, an 11-year-old born with hearing loss, achieved restored hearing “across all tested frequencies, achieving thresholds of 65 to 20 dB HL,” including results within normal hearing range at some frequencies, according to Lilly.
Lilly said it will release more details and additional data from a second patient at this year’s Association for Research in Otolaryngology in February. The company said both the therapy and the surgical procedure were well-tolerated with “no serious adverse events.”
AK-OTOF was the lead candidate at Akouos before it was bought by Eli Lilly in late 2022 for $487 million, plus $123 million in contingent value rights.
Regeneron read out results in October suggesting its rival gene therapy DB-OTO led to improved auditory responses in a child under 2 years old through 6 weeks. The therapy is in an early-stage study in the US, Spain and the UK.
https://endpts.com/eli-lilly-says-its-potential-gene-therapy-restored-hearing-in-11-year-old-boy/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Preclinical Studies Highlight Novel Gene Therapy for IgA Nephropathy Treatment
San Diego, CA – October 28, 2024 At the recent ASN Kidney Week 2024 (October 23–27), researchers presented promising preclinical data on PS-002, an innovative gene therapy aimed at treating IgA nephropathy (IgAN), an autoimmune kidney disease. The therapy, developed...
[2024/10/25] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
Lipin1 Inhibition Enhances Axon Regeneration: A Potential Therapeutic Approach for Spinal Cord Injury
Traumatic injuries to the central nervous system (CNS) often result in permanent functional deficits due to the limited capacity of CNS neurons to regenerate. Although advancements in spinal cord injury (SCI) research have been made, achieving substantial nerve fiber...
CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics announced that an experimental gene editing therapy reduced dangerous and unpredictable swelling attacks caused by the disease hereditary...
Related Services
Plasmids GMP Services
AAV GMP Services
